Get the Stockscreener App
722.07
0.75%
5.35
After Hours:
722.07
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders - GlobeNewswire Inc.
Eye-Catching: Biosimilars Injunction Prevails - The National Law Review
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Billions in Buybacks: 4 Stocks Rewarding Shareholders Now - MarketBeat
Immuneering announces clinical supply agreement with Regeneron - TipRanks
Regeneron Pharmaceuticals (NASDAQ:REGN) Raised to "Strong-Buy" at Leerink Partnrs - MarketBeat
Immuneering and Regeneron partner on lung cancer trial - Investing.com
Immuneering Corporation (IMRX) Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo - StreetInsider.com
Immuneering Partners with Regeneron to Test Novel Cancer Drug Combination for NSCLC | IMRX Stock News - StockTitan
Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for InvestorsContact The Gross Law Firm - Morningstar
Yousif Capital Management LLC Sells 1,077 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
BMO Capital Markets Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $903.00 - Defense World
Leerink Partners Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - Defense World
TD Cowen Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - Defense World
Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight - GuruFocus.com
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire
Examining the Potential Price Growth of Regeneron Pharmaceuticals, Inc (REGN) - Knox Daily
Regeneron’s Eylea Faces Pressure, But Pipeline Shows Strength - Citeline News & Insights
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
RBC cuts Regeneron stock price target to $1,045, keeps Outperform - MSN
Western Financial Corp CA Lowers Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regeneron - GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure - The Bakersfield Californian
Regeneron Is Playing Defense With Capital Allocation (NASDAQ:REGN) - Seeking Alpha
Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target - GlobeNewswire
Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) - GlobeNewswire
Regeneron upgraded at Leerink following recent share weakness - MSN
Amgen obesity drug on hold; Regeneron sets first dividend - BioPharma Dive
Morgan Stanley Adjusts Regeneron Pharmaceuticals Price Target to $1,150 From $1,185 - Marketscreener.com
Regeneron Pharmaceuticals Inc. (REGN) reports earnings - Quartz
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Call Transcript - Insider Monkey
Mirae Asset Global Investments Co. Ltd. Buys 9,845 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Leerink Partners - MarketBeat
Regeneron Presents An Opportunity After LIBTAYO Sales Growth Bolsters Earnings - Seeking Alpha
Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 52-Week LowHere's Why - MarketBeat
Paragon Capital Management Inc. Makes New $1.26 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
China Universal Asset Management Co. Ltd. Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Ninety One UK Ltd - MarketBeat
Factory Mutual Insurance Co. Acquires New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Partners with Truveta to Expand DNA Healthcare Database - The Healthcare Technology Report.
Regeneron Pharmaceuticals Inc (REGN) Q4 2024 Earnings Call Highl - GuruFocus.com
Regeneron Pharmaceuticals Inc (REGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Regeneron Reports Strong 2024 Earnings and Strategic Initiatives - TipRanks
Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday - sharewise
Regeneron (REGN) Shares Surge on Strong Earnings Report - GuruFocus.com
Regeneron Reports Strong Growth and Promising Pipeline - TipRanks
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders - ACCESS Newswire
Morgan Stanley cuts Regeneron stock price target to $1,150 - Investing.com
Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend - Yahoo! Voices
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc.REGN - PR Newswire
RBC Trims Price Target on Regeneron Pharmaceuticals to $1,045 From $1,059, Keeps Outperform Rating - Marketscreener.com
Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid QuarterEylea To Strike Back In 2025 - Seeking Alpha
Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend - Yahoo Finance
Latest Federal Court Cases: Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc. - JD Supra
Regeneron Pharmaceuticals, Inc. Sued for Securities Law - GlobeNewswire
Strong 4th-qtr and full year financials from Regeneron - The Pharma Letter
Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program - Benzinga
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals - GlobeNewswire
Regeneron Pharmaceuticals, Inc. Approves the Initiation of A Quarterly Cash Dividend Program and Declares A Cash Dividend, Payable on March 20, 2025 - Marketscreener.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $903.00 Price Target at BMO Capital Markets - MarketBeat
Regeneron holds off copies of $6bn eye treatment - Life Sciences Intellectual Property Review
Regeneron's Libtayo reaches blockbuster status and has potential for more growth: execs - FiercePharma
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,030.00 Price Target at TD Cowen - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,000.00 Price Target at Bernstein Bank - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $862.00 Price Target at Leerink Partners - MarketBeat
2.05%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):